ClinicalTrials.gg

Program

linaprazan glurate

Also written as “X842”, “Linaprazan glurate” and “Single ascending dose of X842”.

Its studies are mostly in Gastroesophageal Reflux · Esophagitis · Esophagitis, Peptic, led by 2 companies.

Furthest: phase 3, since Jun 17, 202513 company-led studies, 1 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cinclus Pharma Holding AB81 open or runningphase 3since Jun 17, 2025Mar 1, 2017Nov 30, 2026phase 1 · NCT05469854
Jiangsu Sinorda Biomedicine50 open or runningphase 3since Jul 14, 2025Feb 7, 2020none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2017First study: early phase 1 study in Gastroesophageal RefluxNew to Cinclus Pharma Holding ABCinclus Pharma Holding AB · NCT03105375 · 39 enrolled · Sweden
  2. Feb 7, 2020Jiangsu Sinorda Biomedicine's first study: phase 1 study in EsophagitisNew to Jiangsu Sinorda BiomedicineJiangsu Sinorda Biomedicine · NCT04293965 · 80 enrolled · China
  3. Aug 26, 2020Phase 2 study in Esophagitis, PepticJiangsu Sinorda Biomedicine · NCT04531475 · 90 enrolled · China
  4. Sep 14, 2021Phase 2 study in Erosive EsophagitisCinclus Pharma Holding AB · NCT05055128 · 248 enrolled · United States, Bulgaria, Czechia and more
  5. Jul 15, 2022Phase 1 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT05469854 · 121 planned · Sweden
  6. Nov 16, 20222 phase 1 studiesCinclus Pharma Holding AB · NCT05627518, NCT05633147
  7. Jan 2, 2023Phase 1 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT05742984 · 75 enrolled · Slovenia
  8. Jun 17, 2025Phase 3 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT07037875 · 523 enrolled · Bulgaria, Czechia, Georgia and more
  9. Jul 14, 2025Phase 1 study in Gastroesophageal RefluxJiangsu Sinorda Biomedicine · NCT07107672 · 6 enrolled · China
  10. Jul 14, 2025Phase 3 study in Esophagitis, PepticJiangsu Sinorda Biomedicine · NCT07079540 · 380 enrolled · China
  11. Sep 4, 2025Phase 1 study in Healthy VolunteersJiangsu Sinorda Biomedicine · NCT07294846 · 56 enrolled · China
  12. Dec 19, 2025Phase 3 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT07313774

Ahead

  1. Nov 30, 2026Primary completion: phase 1 study in Gastroesophageal RefluxCinclus Pharma Holding AB · NCT05469854

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07313774Gastroesophageal Reflux3WithdrawnCinclus Pharma Holding ABSep 20280
NCT07294846Healthy Volunteers · China1CompletedJiangsu Sinorda BiomedicineDec 15, 202556
NCT07107672Gastroesophageal Reflux · China1CompletedJiangsu Sinorda BiomedicineJul 7, 20226
NCT07079540Esophagitis, Peptic · China3CompletedJiangsu Sinorda BiomedicineJul 27, 2022380
NCT07037875Gastroesophageal Reflux · Bulgaria, Czechia, Georgia and more3CompletedCinclus Pharma Holding ABSep 28, 2026523
NCT05742984Gastroesophageal Reflux · Slovenia1CompletedCinclus Pharma Holding ABMar 24, 202375
NCT05633147Safety Issues · Sweden1CompletedCinclus Pharma Holding ABMay 30, 202335
NCT05627518Safety · Slovenia1CompletedCinclus Pharma Holding ABDec 30, 202267
NCT05469854Gastroesophageal Reflux · Sweden1RecruitingCinclus Pharma Holding ABNov 30, 2026121
NCT05055128Erosive Esophagitis · United States, Bulgaria, Czechia and more2CompletedCinclus Pharma Holding ABSep 1, 2022248
NCT04531475Esophagitis, Peptic · China2CompletedJiangsu Sinorda BiomedicineOct 24, 202090
NCT04293965Esophagitis · China1CompletedJiangsu Sinorda BiomedicineSep 4, 201980
NCT03105375Gastroesophageal Reflux · SwedenEarly 1CompletedCinclus Pharma Holding ABOct 12, 201739

How it is read

Names in the registry

  • “X842”, 3 entries
  • “Linaprazan glurate”, 3 entries
  • “Single ascending dose of X842”, 2 entries
  • “Multiple ascending dose of X842”, 2 entries
  • “Linaprazan glurate 50 mg Twice Daily (BID)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.